BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 32436610)

  • 1. Patterns and predictors of cancer-related fatigue in ovarian and endometrial cancers: 1-year longitudinal study.
    Poort H; de Rooij BH; Uno H; Weng S; Ezendam NPM; van de Poll-Franse L; Wright AA
    Cancer; 2020 Aug; 126(15):3526-3533. PubMed ID: 32436610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serous ovarian, fallopian tube and primary peritoneal cancers: a comparative epidemiological analysis.
    Jordan SJ; Green AC; Whiteman DC; Moore SP; Bain CJ; Gertig DM; Webb PM; ;
    Int J Cancer; 2008 Apr; 122(7):1598-603. PubMed ID: 18058817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health-related quality of life in early breast cancer.
    Groenvold M
    Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A study of symptoms described by ovarian cancer survivors.
    Stavraka C; Ford A; Ghaem-Maghami S; Crook T; Agarwal R; Gabra H; Blagden S
    Gynecol Oncol; 2012 Apr; 125(1):59-64. PubMed ID: 22155797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in health-related quality of life among gynecologic cancer survivors during the two years after initial treatment: a longitudinal analysis.
    Zandbergen N; de Rooij BH; Vos MC; Pijnenborg JMA; Boll D; Kruitwagen RFPM; van de Poll-Franse LV; Ezendam NPM
    Acta Oncol; 2019 May; 58(5):790-800. PubMed ID: 30698069
    [No Abstract]   [Full Text] [Related]  

  • 6. When will I feel normal again? Trajectories and predictors of persistent symptoms and poor wellbeing after primary chemotherapy for ovarian cancer.
    Beesley VL; Webber K; Nagle CM; DeFazio A; Obermair A; Williams M; Friedlander M; Webb PM;
    Gynecol Oncol; 2020 Oct; 159(1):179-186. PubMed ID: 32773150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrence patterns of advanced ovarian, fallopian tube, and peritoneal cancers after complete cytoreduction during interval debulking surgery.
    Usami T; Kato K; Taniguchi T; Abe A; Nomura H; Yamamoto A; Matoda M; Okamoto S; Kondo E; Omatsu K; Kawamata Y; Takeshima N
    Int J Gynecol Cancer; 2014 Jul; 24(6):991-6. PubMed ID: 24905612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.
    Finch A; Beiner M; Lubinski J; Lynch HT; Moller P; Rosen B; Murphy J; Ghadirian P; Friedman E; Foulkes WD; Kim-Sing C; Wagner T; Tung N; Couch F; Stoppa-Lyonnet D; Ainsworth P; Daly M; Pasini B; Gershoni-Baruch R; Eng C; Olopade OI; McLennan J; Karlan B; Weitzel J; Sun P; Narod SA;
    JAMA; 2006 Jul; 296(2):185-92. PubMed ID: 16835424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The results of gynecologic surveillance in families with hereditary nonpolyposis colorectal cancer.
    Ketabi Z; Gerdes AM; Mosgaard B; Ladelund S; Bernstein I
    Gynecol Oncol; 2014 Jun; 133(3):526-30. PubMed ID: 24631699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of a risk-calculator for adverse perioperative outcomes for women with ovarian cancer.
    Cham S; Chen L; St Clair CM; Hou JY; Tergas AI; Melamed A; Ananth CV; Neugut AI; Hershman DL; Wright JD
    Am J Obstet Gynecol; 2019 Jun; 220(6):571.e1-571.e8. PubMed ID: 30771346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of levonorgestrel-releasing intrauterine system use on the cancer risk of the ovary and fallopian tube.
    Soini T; Hurskainen R; Grénman S; Mäenpää J; Paavonen J; Pukkala E
    Acta Oncol; 2016 Nov; 55(11):1281-1284. PubMed ID: 27148621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of peritoneal washing cytology in staging and prognosis of ovarian and fallopian tube neoplasms: a 10-year retrospective analysis.
    Davidson W; Madan R; O'Neil M; Tawfik OW; Fan F
    Ann Diagn Pathol; 2016 Jun; 22():54-7. PubMed ID: 27180061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in the incidence of serous fallopian tube, ovarian, and peritoneal cancer in the US.
    Liao CI; Chow S; Chen LM; Kapp DS; Mann A; Chan JK
    Gynecol Oncol; 2018 May; 149(2):318-323. PubMed ID: 29514737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome.
    Schmeler KM; Lynch HT; Chen LM; Munsell MF; Soliman PT; Clark MB; Daniels MS; White KG; Boyd-Rogers SG; Conrad PG; Yang KY; Rubin MM; Sun CC; Slomovitz BM; Gershenson DM; Lu KH
    N Engl J Med; 2006 Jan; 354(3):261-9. PubMed ID: 16421367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there a taxane-free interval that predicts response to taxanes as a later-line treatment of recurrent ovarian or primary peritoneal cancer?
    McCourt C; Dessie S; Bradley AM; Schwartz J; Brard L; Dizon DS
    Int J Gynecol Cancer; 2009 Apr; 19(3):343-7. PubMed ID: 19407557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer: a reality check: results of stage 1 of the gynecologic cancer intergroup symptom benefit study.
    Friedlander ML; Stockler M; O'Connell R; Voysey M; Oza A; Gillies K; Donovan H; Martyn J; Sjoquist K; Butow P; King MT;
    Int J Gynecol Cancer; 2014 Jun; 24(5):857-64. PubMed ID: 24844219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations among menopausal symptoms, sleep and fatigue in Taiwanese women with endometrial cancer.
    Li CC; Tsai YF; Chang TC; Chen L
    Eur J Cancer Care (Engl); 2017 Sep; 26(5):. PubMed ID: 27545107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High Efficacy and Low Toxicity of the Modified Docetaxel and Carboplatin Protocol in Patients with Recurrent Ovarian Cancer-A Phase 2 Cohort Study.
    Bruchim I; Weeg N; Alpert Y; Sade D; Piura E; Fishman A
    Int J Gynecol Cancer; 2016 May; 26(4):640-7. PubMed ID: 27101523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236).
    Duska LR; Java JJ; Cohn DE; Burger RA
    Gynecol Oncol; 2015 Nov; 139(2):221-7. PubMed ID: 26335594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatigue in ovarian carcinoma patients: a neglected issue?
    Holzner B; Kemmler G; Meraner V; Maislinger A; Kopp M; Bodner T; Nguyen-Van-Tam D; Zeimet AG; Fleischhacker WW; Sperner-Unterweger B
    Cancer; 2003 Mar; 97(6):1564-72. PubMed ID: 12627522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.